Pentravan® Formulation Expansion
Chronic Neuropathic Pain
Key Facts
About Fagron
Fagron's mission is to optimize and innovate personalized medicine by empowering pharmacists worldwide with a comprehensive technology and supply platform for pharmaceutical compounding. The company has achieved global scale, operating in over 30 countries with ~70 facilities, serving as a critical partner in healthcare for tailored treatments. Its strategy revolves around expanding its proprietary science (excipients, equipment), deepening its educational offerings through Fagron Academy, and leveraging its global supply chain to solidify its market-leading position. Fagron's integrated model addresses a persistent gap in mass-produced pharmaceuticals, creating a stable, high-margin business.
View full company profileTherapeutic Areas
Other Chronic Neuropathic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| EGFR Inhibitor (Tyrosine Kinase Inhibitor - oral) | AKIGAI | Preclinical |
| EGFR Inhibitor (Monoclonal Antibody - parenteral) | AKIGAI | Preclinical |
| Modified/Targeted EGFR Inhibitor | AKIGAI | Discovery |